340 related articles for article (PubMed ID: 35129636)
1. Adoptive cell therapies in thoracic malignancies.
Lasvergnas J; Naigeon M; Chouahnia K; Zelek L; Chaput N; Duchemann B
Cancer Immunol Immunother; 2022 Sep; 71(9):2077-2098. PubMed ID: 35129636
[TBL] [Abstract][Full Text] [Related]
2. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer.
Zhao P; Bu X; Wei X; Sun W; Xie X; Li C; Guo Q; Zhu D; Wei X; Gao D
Int Immunopharmacol; 2015 Apr; 25(2):450-6. PubMed ID: 25698555
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.
Tao L; Huang G; Shi S; Chen L
Med Oncol; 2014 Jan; 31(1):777. PubMed ID: 24271420
[TBL] [Abstract][Full Text] [Related]
5. Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC).
Gu Y; Lv H; Zhao J; Li Q; Mu G; Li J; Wuyang J; Lou G; Wang R; Zhang Y; Huang X
Int Immunopharmacol; 2017 Sep; 50():263-269. PubMed ID: 28711032
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery.
Li H; Wang C; Yu J; Cao S; Wei F; Zhang W; Han Y; Ren XB
Cytotherapy; 2009; 11(8):1076-83. PubMed ID: 19929470
[TBL] [Abstract][Full Text] [Related]
7. Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).
Zhao Y; Qiao G; Wang X; Song Y; Zhou X; Jiang N; Zhou L; Huang H; Zhao J; Morse MA; Hobeika A; Ren J; Lyerly HK
Clin Transl Oncol; 2019 Jun; 21(6):721-728. PubMed ID: 30374838
[TBL] [Abstract][Full Text] [Related]
8. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
[TBL] [Abstract][Full Text] [Related]
9. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
10. Cell transfer-based immunotherapies in cancer: A review.
Gorabi AM; Hajighasemi S; Sathyapalan T; Sahebkar A
IUBMB Life; 2020 Apr; 72(4):790-800. PubMed ID: 31633881
[TBL] [Abstract][Full Text] [Related]
11. [Research Progress on Dendritic Cells Combined with Cytokine Induced Killer Cells Immunotherapy for Hematological Malignancies --Review].
Shi J; Ma TT; Liu HS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1235-1239. PubMed ID: 30111437
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer.
Wang S; Wang Z
Int Immunopharmacol; 2015 Sep; 28(1):22-8. PubMed ID: 26013109
[TBL] [Abstract][Full Text] [Related]
14. Cytokine-induced killer cells promote antitumor immunity.
Jiang J; Wu C; Lu B
J Transl Med; 2013 Mar; 11():83. PubMed ID: 23536996
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant cytokine-induced killer cell immunotherapy improves long-term survival in patients with stage I-II non-small cell lung cancer after curative surgery.
Huang J; Zhao X; Zhang Z; Yang S; Chen X; Shen C; Wang L; Qi Y; Zhang Y
Cytotherapy; 2023 Feb; 25(2):202-209. PubMed ID: 36379882
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
17. Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives.
Mandriani B; Pelle' E; Pezzicoli G; Strosberg J; Abate-Daga D; Guarini A; Cives M; Porta C
Cancer Treat Rev; 2021 Nov; 100():102288. PubMed ID: 34525422
[TBL] [Abstract][Full Text] [Related]
18. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
[TBL] [Abstract][Full Text] [Related]
19. Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC.
Song H; Liu S; Zhao Z; Sun W; Wei X; Ma X; Zhao P; Gao D
Int Immunopharmacol; 2017 Nov; 52():197-202. PubMed ID: 28941416
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
